Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14395MR)

This product GTTS-WQ14395MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14395MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2090MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ869MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ2922MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ4917MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ2810MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ11318MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ15200MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ2984MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW